Innovative Approaches in Ovarian Cancer Prevention for BRCA Mutation Carriers
In an effort to combat the high mortality rate of ovarian cancer, a research team led by Maria Spies, professor of biochemistry at the Carver College of Medicine, is exploring revolutionary prevention strategies. The focus is on individuals carrying mutations in the BRCA1 and BRCA2 tumor suppressor genes, who currently face limited and invasive preventive options.
The research initiative will initially evaluate the safety and efficacy of long-term inhibition of RAD52, a DNA repair protein. This involves investigating whether suppressing RAD52 can prevent the loss of functional BRCA alleles in laboratory model systems. Following these initial studies, the team aims to test the effects of RAD52 inhibition in ovarian tumor samples.
Subsequent phases of the research will extend to first-in-human trials, which are designed to assess the safety, appropriate dosing, and overall effectiveness of this novel approach. This ambitious project also brings together experts from various fields, including M. Ashley Spies, professor of pharmaceutical sciences and experimental therapeutics at the College of Pharmacy, and Kristina Thiel, assistant professor of obstetrics and gynecology at the Carver College of Medicine.
Read More Here
